04913nam 22012013a 450 991036775510332120250203235427.09783039213160303921316410.3390/books978-3-03921-316-0(CKB)4100000010106166(oapen)https://directory.doabooks.org/handle/20.500.12854/61518(ScCtBLL)d2470d31-a268-4c86-a181-af97c3ed37bc(OCoLC)1163826911(oapen)doab61518(EXLCZ)99410000001010616620250203i20192019 uu engurmn|---annantxtrdacontentcrdamediacrrdacarrierUnconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological ProfileMaria ContelMDPI - Multidisciplinary Digital Publishing Institute2019Basel, Switzerland :MDPI,2019.1 electronic resource (204 p.)9783039213153 3039213156 For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile.Biology, life sciencesbicssc?-? stackingencapsulationoxindolimine-metal complexescyclodextrinplatinum iodido complexesdistribution coefficientantiproliferative activityanticancer agentsnanotubesrutheniumplatinumLog kwnanoparticlesdrug discoverymetal complexmetallodrugsisatin-derived ligandsanticancer drugupconverting nanoparticlespyridine benzimidazoledendrimersliposomesthiopheneangiogenesismicellesHSA oxidationplatinum(IV)imagingchromatographic lipophilicity parameteramidophosphinecopper and iron chelators in cancerLog PbiomacromoleculesbonesDNA cleavagestopped-flow spectroscopysilverphosphonatestransmetalationmetallomicsMRIfluorescence quenchingpartition coefficientgold fingersanticancerHSA bindinggold?0targetingmetastasisDNA interactionantimigrationcytotoxicityHPLCruthenium complexeszinc finger proteinsGold(III) complexesaquaporinsantiproliferativeprotein-DNA recognitionphotoactivationlipophilicitycancer1-methylcytosinePETBiology, life sciencesContel Maria1328854ScCtBLLScCtBLLBOOK9910367755103321Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile3039033UNINA